Cell/Gene Tx channel feed

Up­dat­ed: Jim Wil­son to step down from gene ther­a­py post at UPenn, will form two new com­pa­nies

11 months ago
People
R&D

Umo­ja to dose first pa­tient with in vi­vo CAR-T by end of this year

11 months ago
R&D
Manufacturing

Ex­clu­sive: Myeloid Ther­a­peu­tics moves sec­ond in vi­vo cell ther­a­py in­to tri­als, tar­get­ing liv­er can­cer

11 months ago
R&D

Pfiz­er cuts 210 North Car­oli­na work­ers af­ter it of­fi­cial­ly dis­con­tin­ues failed Duchenne gene ther­a­py

11 months ago
People
Manufacturing

Arti­va's IPO rais­es $167M to fund com­pa­ny's au­toim­mune and can­cer cell ther­a­pies

11 months ago
Financing
Startups

4DMT builds out case for wet AMD gene ther­a­py with new Phase 2 da­ta

11 months ago
R&D

Ad­verum pre­pares piv­otal study for wet AMD gene ther­a­py, touts Phase 2 da­ta

11 months ago
R&D

Cari­bou to slash pre­clin­i­cal al­lo­gene­ic CAR-NK work, lay off 12% of staff

11 months ago
People
R&D

Af­ter last year's Im­muno­Gen pact, Ver­tex finds an­oth­er con­di­tion­ing agent part­ner in Orum

11 months ago
Startups
Deals

Up­dat­ed: Lex­eo Ther­a­peu­tic­s' gene ther­a­py shows po­ten­tial for Friedre­ich's atax­ia car­diomy­opa­thy with ear­ly da­ta

12 months ago
R&D

Arti­va aims for $116M in sec­ond at­tempt at IPO to boost NK cell ther­a­py pipeline

12 months ago
Financing

Roche's gene ther­a­py biotech Spark is lay­ing off em­ploy­ees, end­ing some ear­ly-stage pro­grams

12 months ago
People

UniQure trum­pets mid-stage da­ta for Hunt­ing­ton's dis­ease gene ther­a­py

Last year
R&D

In­fec­tions are ma­jor cause of non-re­lapse deaths af­ter CAR-T cell ther­a­py, study shows

Last year
R&D

Ex­clu­sive: Gene in­ser­tion start­up launch­es with new in­te­grase tech­nol­o­gy from Uni­ver­si­ty of Hawaii

Last year
Financing
Startups

Bea­con rais­es $170M to take on J&J in oc­u­lar gene ther­a­py

Last year
Financing
Startups

J&J and Leg­end say Carvyk­ti im­proved sur­vival in ear­li­er-line mul­ti­ple myelo­ma

Last year
R&D

Carte­sian clears an au­toim­mune CAR-T tri­al, starts an­oth­er Phase 2 and rais­es $130M

Last year
Financing
R&D

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Last year
FDA+
Manufacturing

Lyell re­ports pa­tient death, ear­ly re­spons­es in sol­id tu­mor CAR-T tri­al

Last year
R&D

Can CRISPR be giv­en twice? Small study from In­tel­lia sug­gests it can

Last year
R&D

Can mR­NA be har­nessed for gene in­ser­tion? Mod­er­na's for­mer chief med­ical of­fi­cer has $82M to find out

Last year
Financing
Startups

Fractyl pitch­es po­ten­tial of GLP-1 gene ther­a­py, but push­es clin­i­cal tri­als back to 2025

Last year
R&D

Pe­ter Marks sin­gle-hand­ed­ly ap­proved Sarep­ta’s gene ther­a­py — what does that mean for every­one else?

Last year
Pharma
FDA+
First page Previous page 567891011 Next page Last page
A service from the Financial Times